Company Overview - Alphatec Holdings is a leading developer of advanced medical devices for spinal surgery, focusing on innovation to address complex spinal pathologies [6] - The company aims to expand its differentiated product portfolio and enhance procedural outcomes for surgeons and patients, primarily targeting the U.S. market [6] - As of the latest data, Alphatec's market capitalization is $1.7 billion, with a revenue of $764.16 million and a net income of -$143.36 million [4] Recent Transaction - John Todd Koning, CFO of Alphatec Holdings, sold 79,789 shares for approximately $986,000, which represents 11.7% of his direct common stock ownership at the time [1][7] - The transaction was executed under a 10b5-1 plan primarily to address tax liabilities, indicating it is a typical liquidity event linked to compensation rather than a reflection of the company's performance [7][9] - Post-transaction, Koning holds 600,721 shares, with a direct ownership value of approximately $7.38 million [2] Financial Performance - In 2025, Alphatec reported total revenues of $764 million, marking a 25% year-over-year increase, alongside significant margin improvements [10] - The company achieved an adjusted EBITDA of $93 million, with margins climbing to 12% as procedural volumes increased [10] - Management forecasts around $890 million in revenue for 2026, suggesting continued double-digit growth [10] Market Position and Strategy - Alphatec offers a comprehensive portfolio of spinal surgery solutions, including neural monitoring systems, fixation devices, interbody implants, and biologics [8] - The firm generates revenue primarily through direct sales and distribution of proprietary medical devices and surgical products to hospitals and surgical centers [8] - The focus remains on growth and enhancing operational efficiency, prioritizing long-term scalability over immediate profits [11]